Uppsala, Might 9, 2023 – OssDsign AB (publ.) immediately pronounces that 1,000 sufferers have been handled within the U.S. with the revolutionary nanosynthetic bone graft OssDsign Catalyst. Product consciousness is growing significantly, which is mirrored within the quickly rising variety of sufferers handled.
OssDsign Catalyst has been very properly acquired within the U.S. market since its launch in August 2021. In January OssDsign reported that 500 sufferers had been handled since launch, and initially of Might the quantity elevated to 1,000 sufferers.
“OssDsign Catalyst is rising exponentially pushed by a repeatedly rising buyer base in addition to broader utilization inside the hospitals and, within the final 4 months alone, now we have doubled the variety of sufferers handled. That is an excellent improvement that highlights the potential for OssDsign Catalyst to turn out to be the popular product for spinal fusion surgical procedures,” stated Morten Henneveld, CEO of OssDsign.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of wholesome bone tissue in spinal fusion surgical procedures. The graft consists of a proprietary nanocrystalline construction which is resorbed and changed by new and wholesome bone tissue. The product was launched within the U.S. in August 2021. The market clearance within the U.S. is predicated on preclinical outcomes that surpass what is usually seen with different artificial bone grafts in essentially the most demanding preclinical mannequin for spinal fusion – the Boden mannequin. OssDsign continues to speed up a sturdy program of gathering scientific proof anchored by PROPEL, a U.S.-based multi-center potential spinal fusion registry, and the scientific examine TOP FUSION, through which affected person enrolment was accomplished in April 2022.
For additional data, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, electronic mail: email@example.com
Erik Penser Financial institution AB is the corporate’s Licensed Adviser. Contact data: Erik Penser Financial institution AB, Field 7405, 103 91 Stockholm, Sweden, cellphone: +46 (0)8-463 80 00, electronic mail: firstname.lastname@example.org
OssDsign is a developer and world supplier of subsequent era bone alternative merchandise. Primarily based on innovative materials science, the corporate develops and markets merchandise that help the physique’s personal therapeutic capabilities and thereby enhance the scientific end result in a variety of orthopedic areas with excessive medical wants. With a product portfolio consisting of patient-specific implants for cranial surgical procedures and an off-the-shelf artificial bone graft for spine surgical procedures, OssDsign give sufferers again the life they deserve. The corporate has a robust business presence within the U.S., Europe and chosen Asian international locations. OssDsign’s share is traded on Nasdaq First North Progress Market in Stockholm, Sweden.